1
|
Ahmadi M, Emzhik M, Mosayebnia M. Nanoparticles labeled with gamma-emitting radioisotopes: an attractive approach for in vivo tracking using SPECT imaging. Drug Deliv Transl Res 2023; 13:1546-1583. [PMID: 36811810 DOI: 10.1007/s13346-023-01291-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/03/2023] [Indexed: 02/24/2023]
Abstract
Providing accurate molecular imaging of the body and biological process is critical for diagnosing disease and personalizing treatment with the minimum side effects. Recently, diagnostic radiopharmaceuticals have gained more attention in precise molecular imaging due to their high sensitivity and appropriate tissue penetration depth. The fate of these radiopharmaceuticals throughout the body can be traced using nuclear imaging systems, including single-photon emission computed tomography (SPECT) and positron emission tomography (PET) modalities. In this regard, nanoparticles are attractive platforms for delivering radionuclides into targets because they can directly interfere with the cell membranes and subcellular organelles. Moreover, applying radiolabeled nanomaterials can decrease their toxicity concerns because radiopharmaceuticals are usually administrated at low doses. Therefore, incorporating gamma-emitting radionuclides into nanomaterials can provide imaging probes with valuable additional properties compared to the other carriers. Herein, we aim to review (1) the gamma-emitting radionuclides used for labeling different nanomaterials, (2) the approaches and conditions adopted for their radiolabeling, and (3) their application. This study can help researchers to compare different radiolabeling methods in terms of stability and efficiency and choose the best way for each nanosystem.
Collapse
Affiliation(s)
- Mahnaz Ahmadi
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Marjan Emzhik
- Department of Pharmaceutics and Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
| | - Mona Mosayebnia
- Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Niayesh Junction, Vali-E-Asr Ave, Tehran, 14155-6153, Iran.
| |
Collapse
|
2
|
Lankoff A, Czerwińska M, Kruszewski M. Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer. Molecules 2023; 28:molecules28104122. [PMID: 37241862 DOI: 10.3390/molecules28104122] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Revised: 04/24/2023] [Accepted: 05/11/2023] [Indexed: 05/28/2023] Open
Abstract
Prostate cancer is the second most frequent malignancy in men worldwide and the fifth leading cause of death by cancer. Although most patients initially benefit from therapy, many of them will progress to metastatic castration-resistant prostate cancer, which still remains incurable. The significant mortality and morbidity rate associated with the progression of the disease results mainly from a lack of specific and sensitive prostate cancer screening systems, identification of the disease at mature stages, and failure of anticancer therapy. To overcome the limitations of conventional imaging and therapeutic strategies for prostate cancer, various types of nanoparticles have been designed and synthesized to selectively target prostate cancer cells without causing toxic side effects to healthy organs. The purpose of this review is to briefly discuss the selection criteria of suitable nanoparticles, ligands, radionuclides, and radiolabelling strategies for the development of nanoparticle-based radioconjugates for targeted imaging and therapy of prostate cancer and to evaluate progress in the field, focusing attention on their design, specificity, and potential for detection and/or therapy.
Collapse
Affiliation(s)
- Anna Lankoff
- Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
- Department of Medical Biology, Institute of Biology, Jan Kochanowski University, Uniwersytecka 15, 25-406 Kielce, Poland
| | - Malwina Czerwińska
- Department of Dietetics, Institute of Human Nutrition Sciences, Warsaw University of Life Sciences (WULS-SGGW), 159c Nowoursynowska, 02-776 Warsaw, Poland
| | - Marcin Kruszewski
- Centre for Radiobiology and Biological Dosimetry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland
- Department of Molecular Biology and Translational Research, Institute of Rural Health, Jaczewskiego 2, 20-090 Lublin, Poland
| |
Collapse
|
3
|
Sidorenko GV, Miroslavov AE, Tyupina MY. Technetium(I) carbonyl complexes for nuclear medicine: Coordination-chemical aspect. Coord Chem Rev 2023. [DOI: 10.1016/j.ccr.2022.214911] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
4
|
Mattern A, Habermann S, Zegke M, Wickleder MS, Alberto R. High-Yield 99mTc Labeling of Gold Nanoparticles Carrying Atropine and Adrenaline. Bioconjug Chem 2022; 33:1741-1749. [PMID: 35973128 DOI: 10.1021/acs.bioconjchem.2c00351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
This work focuses on the synthesis, purification, and analytical characterization of novel multifunctional Au NPs radiolabeled with 99mTc. These mixed-ligand shell Au NPs represent pharmacologically relevant samples for potential application in theragnostics. A ligand using a plain linker with a rather long chain consisting of 10 CH2 groups and a thiol moiety along with the PADA chelator has been used for both the attachment to the Au NP surface and for the 99mTc(CO)3+ complexation. We have combined this with our approach of stabilizing Au NP without any PEG or other stabilizing groups. Thus, monoligand shell Au NPs were radiolabeled by different strategies (prelabeling and postlabeling). Additionally, pharmacologically relevant Au NPs were synthesized carrying both a biofunctionalization with either atropine or adrenaline and the 99mTc radiolabel. All samples were obtained in very good yields (up to 80% of the total activity loaded onto the column) and completely/particularly purified using desalting columns. Detailed analytical characterization of the Au NPs before and after radiolabeling has proven the NPs' robustness throughout the process. Their intact functionalization, shape, and stability was confirmed by transmission electron microscopy (TEM), ultraviolet/visible (UV/vis) spectroscopy, dynamic light scattering (DLS), and infrared (IR) spectroscopy. The presented strategy represents a versatile building block system that can be adapted to a variety of bioactive molecules and may be of high relevance for theragnostic applications.
Collapse
Affiliation(s)
- Annabelle Mattern
- Institute of Inorganic Chemistry, University of Cologne, Greinstraße 6, 50939 Cologne, Germany
| | - Sebastian Habermann
- Institute of Inorganic Chemistry, University of Cologne, Greinstraße 6, 50939 Cologne, Germany
| | - Markus Zegke
- Institute of Inorganic Chemistry, University of Cologne, Greinstraße 6, 50939 Cologne, Germany
| | | | - Roger Alberto
- Department of Chemistry, University of Zurich, Winterthurer Strasse 190, 8057 Zurich, Switzerland
| |
Collapse
|
5
|
Brunello S, Salvarese N, Carpanese D, Gobbi C, Melendez-Alafort L, Bolzati C. A Review on the Current State and Future Perspectives of [ 99mTc]Tc-Housed PSMA-i in Prostate Cancer. Molecules 2022; 27:molecules27092617. [PMID: 35565970 PMCID: PMC9099988 DOI: 10.3390/molecules27092617] [Citation(s) in RCA: 13] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Revised: 04/12/2022] [Accepted: 04/12/2022] [Indexed: 02/01/2023] Open
Abstract
Recently, prostate-specific membrane antigen (PSMA) has gained momentum in tumor nuclear molecular imaging as an excellent target for both the diagnosis and therapy of prostate cancer. Since 2008, after years of preclinical research efforts, a plentitude of radiolabeled compounds mainly based on low molecular weight PSMA inhibitors (PSMA-i) have been described for imaging and theranostic applications, and some of them have been transferred to the clinic. Most of these compounds include radiometals (e.g., 68Ga, 64Cu, 177Lu) for positron emission tomography (PET) imaging or endoradiotherapy. Nowadays, although the development of new PET tracers has caused a significant drop in single-photon emission tomography (SPECT) research programs and the development of new technetium-99m (99mTc) tracers is rare, this radionuclide remains the best atom for SPECT imaging owing to its ideal physical decay properties, convenient availability, and rich and versatile coordination chemistry. Indeed, 99mTc still plays a relevant role in diagnostic nuclear medicine, as the number of clinical examinations based on 99mTc outscores that of PET agents and 99mTc-PSMA SPECT/CT may be a cost-effective alternative for 68Ga-PSMA PET/CT. This review aims to give an overview of the specific features of the developed [99mTc]Tc-tagged PSMA agents with particular attention to [99mTc]Tc-PSMA-i. The chemical and pharmacological properties of the latter will be compared and discussed, highlighting the pros and cons with respect to [68Ga]Ga-PSMA11.
Collapse
Affiliation(s)
- Sara Brunello
- Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy; (S.B.); (N.S.)
| | - Nicola Salvarese
- Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy; (S.B.); (N.S.)
| | - Debora Carpanese
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35124 Padova, Italy;
| | - Carolina Gobbi
- Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Via Marzolo 5, 35131 Padova, Italy;
| | - Laura Melendez-Alafort
- Immunology and Molecular Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Via Gattamelata 64, 35124 Padova, Italy;
- Correspondence: (L.M.-A.); (C.B.)
| | - Cristina Bolzati
- Institute of Condensed Matter Chemistry and Technologies for Energy ICMATE-CNR, Corso Stati Uniti 4, 35127 Padova, Italy; (S.B.); (N.S.)
- Correspondence: (L.M.-A.); (C.B.)
| |
Collapse
|
6
|
Akber Aisa H, Zhao J, Guo H, Nie L, Bozorov K. Synthesis and Antitumor Activity of Novel Linear Tricyclic Compounds Derived from Purine. HETEROCYCLES 2022. [DOI: 10.3987/com-22-14652] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
7
|
Behroozi Z, Rahimi B, Kookli K, Safari MS, Hamblin MR, Razmgir M, Janzadeh A, Ramezani F. Distribution of gold nanoparticles into the brain: a systematic review and meta-analysis. Nanotoxicology 2021; 15:1059-1072. [PMID: 34591733 DOI: 10.1080/17435390.2021.1966116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Despite the widespread use of gold nanoparticles (GNPs), there is no consensus on their distribution to different tissues and organs. The present systematic review and meta-analysis addresses the accumulation of GNPs in brain tissue. Extensive searches were conducted in electronic databases, Medline, Web of Science, EMBASE, and Scopus. Based on inclusion and exclusion criteria, primary and secondary screening was performed. The value of brain accumulation of gold nanoparticle (the percentage of the injection dose of GNPs/gram of brain tissue that applied as effect size (ES) in analysis) and the standard error of the mean were extracted from articles and analyzed by calculating the pooled ES and the pooled confidence interval (CI) using STATA software. p ≤ 0.05 was considered significant. Thirty-eight studies were included in the meta-analysis. The results showed that the amount of GNPs was 0.06% of the injection dose/gram of brain tissue (ES = 0.06, %95 CI: 0.06-0.06, p < 0.0001). Considering the time between injection and tissue harvest (follow-up time), after 1 h the GNPs in brain tissue was 0.288% of the injection dose/gram of tissue (ES = 0.29, 95% CI: 0.25-0.33, p < 0.0001), while after four weeks it was only 0.02% (ES = 0.02, 95% CI: 0.01-0.03, p < 0.0001) of the injection dose/gram of tissue. The amount of GNPs in brain tissue was higher for PEG-coated GNPs compared to uncoated GNPs, and it was 5.6 times higher for rod-shaped GNPs compared to spherical GNPs. The mean amount of GNPs in the brain tissues of animals bearing a tumor was 5.8 times higher than in normal animals.
Collapse
Affiliation(s)
- Zahra Behroozi
- Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Behnaz Rahimi
- Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
| | - Keihan Kookli
- International campus, Iran University of Medical Sciences, Tehran, Iran
| | - Mohammad S Safari
- Veterinary Faculty of Science and Research Branch, Islamic Azad University, Tehran, Iran
| | - Michael R Hamblin
- Laser Research Centre, Faculty of Health Science, University of Johannesburg, Doornfontein, South Africa
| | - Maryam Razmgir
- Medical Librarianship and Information Science, School of Health Management and Information Sciences, Iran University of Medical Sciences, Tehran, Iran
| | - Atousa Janzadeh
- Radiation Biology Research Center, Iran University of Medical Sciences, Tehran, Iran
| | - Fatemeh Ramezani
- Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
8
|
Apostolopoulou A, Chiotellis A, Salvanou EA, Makrypidi K, Tsoukalas C, Kapiris F, Paravatou-Petsotas M, Papadopoulos M, Pirmettis IC, Koźmiński P, Bouziotis P. Synthesis and In Vitro Evaluation of Gold Nanoparticles Functionalized with Thiol Ligands for Robust Radiolabeling with 99mTc. NANOMATERIALS (BASEL, SWITZERLAND) 2021; 11:2406. [PMID: 34578721 PMCID: PMC8471789 DOI: 10.3390/nano11092406] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 09/08/2021] [Accepted: 09/10/2021] [Indexed: 12/12/2022]
Abstract
Radiolabeled gold nanoparticles (AuNPs) have been widely used for cancer diagnosis and therapy over recent decades. In this study, we focused on the development and in vitro evaluation of four new Au nanoconjugates radiolabeled with technetium-99m (99mTc) via thiol-bearing ligands attached to the NP surface. More specifically, AuNPs of two different sizes (2 nm and 20 nm, referred to as Au(2) and Au(20), respectively) were functionalized with two bifunctional thiol ligands (referred to as L1H and L2H). The shape, size, and morphology of both bare and ligand-bearing AuNPs were characterized by transmission electron microscopy (TEM) and dynamic light scattering (DLS) techniques. In vitro cytotoxicity was assessed in 4T1 murine mammary cancer cells. The AuNPs were successfully radiolabeled with 99mTc-carbonyls at high radiochemical purity (>95%) and showed excellent in vitro stability in competition studies with cysteine and histidine. Moreover, lipophilicity studies were performed in order to determine the lipophilicity of the radiolabeled conjugates, while a hemolysis assay was performed to investigate the biocompatibility of the bare and functionalized AuNPs. We have shown that the functionalized AuNPs developed in this study lead to stable radiolabeled nanoconstructs with the potential to be applied in multimodality imaging or for in vivo tracking of drug-carrying AuNPs.
Collapse
Affiliation(s)
- Adamantia Apostolopoulou
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
- Department of Pharmacy, National and Kapodistrian University of Athens, Panepistimiopolis Zographou, 15771 Athens, Greece
| | - Aristeidis Chiotellis
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Evangelia-Alexandra Salvanou
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Konstantina Makrypidi
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Charalampos Tsoukalas
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Fotis Kapiris
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Maria Paravatou-Petsotas
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Minas Papadopoulos
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Ioannis C. Pirmettis
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| | - Przemysław Koźmiński
- Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16 Str., 03-195 Warsaw, Poland;
| | - Penelope Bouziotis
- National Center for Scientific Research “Demokritos”, Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, Agia Paraskevi, 15341 Athens, Greece; (A.A.); (A.C.); (E.-A.S.); (K.M.); (C.T.); (F.K.); (M.P.-P.); (M.P.); (I.C.P.)
| |
Collapse
|
9
|
Omabe K, Paris C, Lannes F, Taïeb D, Rocchi P. Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes. Pharmaceutics 2021; 13:591. [PMID: 33919150 PMCID: PMC8143094 DOI: 10.3390/pharmaceutics13050591] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2021] [Revised: 04/06/2021] [Accepted: 04/08/2021] [Indexed: 12/21/2022] Open
Abstract
Prostate cancer (PC) is the most frequent male cancer in the Western world. Progression to Castration Resistant Prostate Cancer (CRPC) is a known consequence of androgen withdrawal therapy, making CRPC an end-stage disease. Combination of cytotoxic drugs and hormonal therapy/or genotherapy is a recognized modality for the treatment of advanced PC. However, this strategy is limited by poor bio-accessibility of the chemotherapy to tumor sites, resulting in an increased rate of collateral toxicity and incidence of multidrug resistance (MDR). Nanovectorization of these strategies has evolved to an effective approach to efficacious therapeutic outcomes. It offers the possibility to consolidate their antitumor activity through enhanced specific and less toxic active or passive targeting mechanisms, as well as enabling diagnostic imaging through theranostics. While studies on nanomedicine are common in other cancer types, only a few have focused on prostate cancer. This review provides an in-depth knowledge of the principles of nanotherapeutics and nanotheranostics, and how the application of this rapidly evolving technology can clinically impact CRPC treatment. With particular reference to respective nanovectors, we draw clinical and preclinical evidence, demonstrating the potentials and prospects of homing nanovectorization into CRPC treatment strategies.
Collapse
Affiliation(s)
- Kenneth Omabe
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, 13273 Marseille, France; (K.O.); (C.P.); (F.L.); (D.T.)
- Department of Biochemistry & Molecular Biology, Alex Ekwueme Federal University, Ndufu-Alike Ikwo, PMB 1010, Abakaliki 84001, Nigeria
| | - Clément Paris
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, 13273 Marseille, France; (K.O.); (C.P.); (F.L.); (D.T.)
| | - François Lannes
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, 13273 Marseille, France; (K.O.); (C.P.); (F.L.); (D.T.)
| | - David Taïeb
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, 13273 Marseille, France; (K.O.); (C.P.); (F.L.); (D.T.)
- Biophysics and Nuclear Medicine, La Timone University Hospital, European Center for Research in Medical Imaging, Aix-Marseille University, 13005 Marseille, France
| | - Palma Rocchi
- Centre de Recherche en Cancérologie de Marseille, CRCM, Inserm UMR1068, CNRS UMR7258, Aix-Marseille University U105, Institut Paoli-Calmettes, 13273 Marseille, France; (K.O.); (C.P.); (F.L.); (D.T.)
| |
Collapse
|
10
|
Pellico J, Gawne PJ, T M de Rosales R. Radiolabelling of nanomaterials for medical imaging and therapy. Chem Soc Rev 2021; 50:3355-3423. [PMID: 33491714 DOI: 10.1039/d0cs00384k] [Citation(s) in RCA: 112] [Impact Index Per Article: 37.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
Nanomaterials offer unique physical, chemical and biological properties of interest for medical imaging and therapy. Over the last two decades, there has been an increasing effort to translate nanomaterial-based medicinal products (so-called nanomedicines) into clinical practice and, although multiple nanoparticle-based formulations are clinically available, there is still a disparity between the number of pre-clinical products and those that reach clinical approval. To facilitate the efficient clinical translation of nanomedicinal-drugs, it is important to study their whole-body biodistribution and pharmacokinetics from the early stages of their development. Integrating this knowledge with that of their therapeutic profile and/or toxicity should provide a powerful combination to efficiently inform nanomedicine trials and allow early selection of the most promising candidates. In this context, radiolabelling nanomaterials allows whole-body and non-invasive in vivo tracking by the sensitive clinical imaging techniques positron emission tomography (PET), and single photon emission computed tomography (SPECT). Furthermore, certain radionuclides with specific nuclear emissions can elicit therapeutic effects by themselves, leading to radionuclide-based therapy. To ensure robust information during the development of nanomaterials for PET/SPECT imaging and/or radionuclide therapy, selection of the most appropriate radiolabelling method and knowledge of its limitations are critical. Different radiolabelling strategies are available depending on the type of material, the radionuclide and/or the final application. In this review we describe the different radiolabelling strategies currently available, with a critical vision over their advantages and disadvantages. The final aim is to review the most relevant and up-to-date knowledge available in this field, and support the efficient clinical translation of future nanomedicinal products for in vivo imaging and/or therapy.
Collapse
Affiliation(s)
- Juan Pellico
- School of Biomedical Engineering & Imaging Sciences, King's College London, St. Thomas' Hospital, London SE1 7EH, UK.
| | | | | |
Collapse
|
11
|
Yap SY, Savoie H, Renard I, Burke BP, Sample HC, Michue-Seijas S, Archibald SJ, Boyle RW, Stasiuk GJ. Synthesis of a porphyrin with histidine-like chelate: an efficient path towards molecular PDT/SPECT theranostics. Chem Commun (Camb) 2020; 56:11090-11093. [PMID: 32812554 DOI: 10.1039/d0cc03958f] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
The goal of "personalised" medicine has seen a growing interest in the development of theranostic agents. Bifunctional, and targeted-trifunctional, theranostic water-soluble porphyrins with a histidine-like chelating group have been synthesised via copper-catalysed azide-alkyne cycloaddition (CuAAC) "click" chemistry in high yield and purity. They are capable of photodynamic treatment and [99mTc(CO)3]+ complexation for single-photon emission computed tomography (SPECT) imaging, with a radiochemical yield of >95%. The toxicity and phototoxicity were evaluated on HT-29 cells, DU145, and DU145-PSMA cell lines, with the targeted theranostic showing more potent phototoxicity towards DU145-PSMA expressing cells.
Collapse
Affiliation(s)
- Steven Y Yap
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Huguette Savoie
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Isaline Renard
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Benjamin P Burke
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Harry C Sample
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Saul Michue-Seijas
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Stephen J Archibald
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Positron Emission Tomography Research Centre, University of Hull, Cottingham Road, Hull, HU6 7RX, UK
| | - Ross W Boyle
- Department of Chemistry and Biochemistry, Faculty of Science and Engineering, University of Hull, HU6 7RX, UK.
| | - Graeme J Stasiuk
- Department of Biomedical Sciences, University of Hull, Cottingham Road, Hull, HU6 7RX, UK and Department of Imaging Chemistry and Biology, School of Biomedical Engineering and Imaging Sciences, King's College London, Fourth Floor Lambeth Wing, St Thomas' Hospital, London SE1 7EH, UK.
| |
Collapse
|
12
|
Böhmer VI, Szymanski W, van den Berg K, Mulder C, Kobauri P, Helbert H, van der Born D, Reeβing F, Huizing A, Klopstra M, Samplonius DF, Antunes IF, Sijbesma JWA, Luurtsema G, Helfrich W, Visser TJ, Feringa BL, Elsinga PH. Modular Medical Imaging Agents Based on Azide-Alkyne Huisgen Cycloadditions: Synthesis and Pre-Clinical Evaluation of 18 F-Labeled PSMA-Tracers for Prostate Cancer Imaging. Chemistry 2020; 26:10871-10881. [PMID: 32315486 PMCID: PMC7496508 DOI: 10.1002/chem.202001795] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2020] [Indexed: 01/24/2023]
Abstract
Since the seminal contribution of Rolf Huisgen to develop the [3+2] cycloaddition of 1,3-dipolar compounds, its azide-alkyne variant has established itself as the key step in numerous organic syntheses and bioorthogonal processes in materials science and chemical biology. In the present study, the copper(I)-catalyzed azide-alkyne cycloaddition was applied for the development of a modular molecular platform for medical imaging of the prostate-specific membrane antigen (PSMA), using positron emission tomography. This process is shown from molecular design, through synthesis automation and in vitro studies, all the way to pre-clinical in vivo evaluation of fluorine-18- labeled PSMA-targeting 'F-PSMA-MIC' radiotracers (t1/2 =109.7 min). Pre-clinical data indicate that the modular PSMA-scaffold has similar binding affinity and imaging properties to the clinically used [68 Ga]PSMA-11. Furthermore, we demonstrated that targeting the arene-binding in PSMA, facilitated through the [3+2]cycloaddition, can improve binding affinity, which was rationalized by molecular modeling. The here presented PSMA-binding scaffold potentially facilitates easy coupling to other medical imaging moieties, enabling future developments of new modular imaging agents.
Collapse
Affiliation(s)
- Verena I. Böhmer
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Wiktor Szymanski
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Keimpe‐Oeds van den Berg
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Chantal Mulder
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Piermichele Kobauri
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Hugo Helbert
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | | | - Friederike Reeβing
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Anja Huizing
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | | | - Douwe F. Samplonius
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Ines F. Antunes
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Jürgen W. A. Sijbesma
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Gert Luurtsema
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | - Wijnand Helfrich
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| | | | - Ben L. Feringa
- Stratingh Institute for ChemistryUniversity of GroningenNijenborgh 49747 AFGroningenThe Netherlands
| | - Philip H. Elsinga
- Department of Nuclear Medicine and Molecular ImagingDepartment of RadiologyDepartment of Surgical OncologyUniversity of GroningenUniversity Medical Center GroningenHanzeplein 19713 GZGroningenThe Netherlands
| |
Collapse
|
13
|
Frei A, Fischer E, Childs BC, Holland JP, Alberto R. Two is better than one: difunctional high-affinity PSMA probes based on a [CpM(CO) 3] (M = Re/ 99mTc) scaffold. Dalton Trans 2020; 48:14600-14605. [PMID: 31549121 DOI: 10.1039/c9dt02506e] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
More than 10% of all men will be given the diagnosis "prostate cancer" during their lifetime. Most of the current radio-diagnostic vehicles involve both expensive and localized production with cyclotrons as well as the use of bulky chelators for the radiometal. We report the use of a new multifunctional cyclopentadiene (Cp) platform to prepare difunctional and monofunctional, PSMA-targeting rhenium and technetium-99m complexes. The Cp-complexes and the free ligands are prepared by straightforward functionalization with either one or two Lys-urea-Glu (LuG) PSMA binding motifs. Cell binding assays revealed that the difunctional rhenium complex displays a dissociation constant (KD = 2.1 nM) that is an order of magnitude lower than the monofunctional compound (KD = 24.2 nM). The 99mTc complexes can be prepared in one step and ≤15 min in high yields. These difunctional Cp-Re(i)/99mTc(i) complexes represent a new class of imaging agents with binding affinities comparable to clinically evaluated compounds. Additionally, this study demonstrates that the Cp-platform can readily be derivatized with amine-containing biomolecules. Extending this work to incorporate both targeting and therapeutic moieties could lead to theranostic systems with Re/99mTc.
Collapse
Affiliation(s)
- Angelo Frei
- Department of Chemistry, University of Zürich, Winterthurerstr. 190, CH-8057 Zürich, Switzerland.
| | | | | | | | | |
Collapse
|
14
|
|
15
|
|
16
|
Affiliation(s)
- F M Mottaghy
- University Hospital RWTH Aachen University, Dept. of Nuclear Medicine, Pauwelsstr. 30, 52057 Aachen, Germany; Dept. of Radiology and Nuclear Medicine, Maastricht University Medical Center, Maastricht, The Netherlands.
| |
Collapse
|
17
|
Pant K, Pufe J, Zarschler K, Bergmann R, Steinbach J, Reimann S, Haag R, Pietzsch J, Stephan H. Surface charge and particle size determine the metabolic fate of dendritic polyglycerols. NANOSCALE 2017; 9:8723-8739. [PMID: 28616954 DOI: 10.1039/c7nr01702b] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
Dendritic polyglycerols (dPG) are water soluble, polyether-based nanomaterials which hold great potential in diagnostic as well as therapeutic applications. In order to translate them for in vivo applications, a systematic assessment regarding their cell and tissue interactions as well as their metabolic fate in vivo is a crucial step. Herein, we explore the structure-activity relationship of three different sizes (ca. 3, 5, and 10 nm) of neutral dendritic polyglycerol (dPG) and their corresponding negatively charged sulfate analogs (dPGS) on their in vitro and in vivo characteristics. Cellular metabolic activity was studied in A431 and HEK293 cells. Biomolecular corona formation was determined using an electrophoretic mobility shift assay, which showed an increased protein binding of the dPGS even with serum concentrations as low as 20%. An in situ technique, microscale thermophoresis, was employed to address the binding affinities of these nanomaterials with serum proteins such as serum albumin, apo-transferrin, and fibrinogen. In addition, nanoparticle-cell interactions were studied in differentiated THP-1 cells which showed a charge dependent scavenger receptor-mediated uptake. In line with this data, detailed biodistribution and small animal PET imaging studies in Wistar rats using 68Ga-labeled dPG-/dPGS-NOTA conjugates showed that the neutral dPG-NOTA conjugates were quantitatively excreted via the kidneys with a subsequent hepatobiliary excretion with an increase in their size, whereas the polysulfated analogs (dPGS-NOTA) were sequestered preferentially in the liver and kidneys irrespective of their size. Taken together, this systematic study accentuates that the pharmacokinetics of dPGs is critically dependent on the overall size and charge and can be, fine-tuned for the intended requirements in nano-theranostics.
Collapse
Affiliation(s)
- Kritee Pant
- Helmholtz-Zentrum Dresden - Rossendorf, Institute of Radiopharmaceutical Cancer Research, Bautzner Landstrasse 400, D-01328 Dresden, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Silva F, Fernandes C, Campello MPC, Paulo A. Metal complexes of tridentate tripod ligands in medical imaging and therapy. Polyhedron 2017. [DOI: 10.1016/j.poly.2016.11.040] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
19
|
Fernandes RS, dos Santos Ferreira D, de Aguiar Ferreira C, Giammarile F, Rubello D, de Barros ALB. Development of imaging probes for bone cancer in animal models. A systematic review. Biomed Pharmacother 2016; 83:1253-1264. [DOI: 10.1016/j.biopha.2016.08.039] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2016] [Revised: 08/12/2016] [Accepted: 08/15/2016] [Indexed: 12/13/2022] Open
|
20
|
Zarschler K, Rocks L, Licciardello N, Boselli L, Polo E, Garcia KP, De Cola L, Stephan H, Dawson KA. Ultrasmall inorganic nanoparticles: State-of-the-art and perspectives for biomedical applications. NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE 2016; 12:1663-701. [PMID: 27013135 DOI: 10.1016/j.nano.2016.02.019] [Citation(s) in RCA: 182] [Impact Index Per Article: 22.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2015] [Revised: 02/08/2016] [Accepted: 02/15/2016] [Indexed: 12/31/2022]
Abstract
Ultrasmall nanoparticulate materials with core sizes in the 1-3nm range bridge the gap between single molecules and classical, larger-sized nanomaterials, not only in terms of spatial dimension, but also as regards physicochemical and pharmacokinetic properties. Due to these unique properties, ultrasmall nanoparticles appear to be promising materials for nanomedicinal applications. This review overviews the different synthetic methods of inorganic ultrasmall nanoparticles as well as their properties, characterization, surface modification and toxicity. We moreover summarize the current state of knowledge regarding pharmacokinetics, biodistribution and targeting of nanoscale materials. Aside from addressing the issue of biomolecular corona formation and elaborating on the interactions of ultrasmall nanoparticles with individual cells, we discuss the potential diagnostic, therapeutic and theranostic applications of ultrasmall nanoparticles in the emerging field of nanomedicine in the final part of this review.
Collapse
Affiliation(s)
- Kristof Zarschler
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf, Bautzner Landstraße 400, Dresden, Germany.
| | - Louise Rocks
- Centre For BioNano Interactions (CBNI), School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
| | - Nadia Licciardello
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf, Bautzner Landstraße 400, Dresden, Germany; Laboratoire de Chimie et des Biomatériaux Supramoléculaires, Institut de Science et d'Ingénierie Supramoléculaires (ISIS), 8 allée Gaspard Monge, Strasbourg, France; Institut für Nanotechnologie (INT), Karlsruher Institut für Technologie (KIT) Campus North, Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen, Germany
| | - Luca Boselli
- Centre For BioNano Interactions (CBNI), School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
| | - Ester Polo
- Centre For BioNano Interactions (CBNI), School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
| | - Karina Pombo Garcia
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf, Bautzner Landstraße 400, Dresden, Germany
| | - Luisa De Cola
- Laboratoire de Chimie et des Biomatériaux Supramoléculaires, Institut de Science et d'Ingénierie Supramoléculaires (ISIS), 8 allée Gaspard Monge, Strasbourg, France; Institut für Nanotechnologie (INT), Karlsruher Institut für Technologie (KIT) Campus North, Hermann-von-Helmholtz-Platz 1, Eggenstein-Leopoldshafen, Germany
| | - Holger Stephan
- Institute of Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden - Rossendorf, Bautzner Landstraße 400, Dresden, Germany
| | - Kenneth A Dawson
- Centre For BioNano Interactions (CBNI), School of Chemistry and Chemical Biology, University College Dublin, Belfield, Dublin 4, Ireland
| |
Collapse
|
21
|
Imstepf S, Pierroz V, Raposinho P, Felber M, Fox T, Fernandes C, Gasser G, Santos IR, Alberto R. Towards99mTc-based imaging agents with effective doxorubicin mimetics: a molecular and cellular study. Dalton Trans 2016; 45:13025-33. [DOI: 10.1039/c6dt00871b] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
99mTc and Re conjugates of Doxorubicin accumulate in the nucleus, bind tightly to DNA and retain hTopoII inhibition.
Collapse
Affiliation(s)
- S. Imstepf
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
| | - V. Pierroz
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
- Institute of Molecular Cancer Research
| | - P. Raposinho
- Centro de Ciências e Tecnologias Nucleares
- Universidade de Lisboa
- PT-2695-066 Bobadela LRS
- Portugal
| | - M. Felber
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
| | - T. Fox
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
| | - C. Fernandes
- Centro de Ciências e Tecnologias Nucleares
- Universidade de Lisboa
- PT-2695-066 Bobadela LRS
- Portugal
| | - G. Gasser
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
| | - I. R. Santos
- Centro de Ciências e Tecnologias Nucleares
- Universidade de Lisboa
- PT-2695-066 Bobadela LRS
- Portugal
| | - R. Alberto
- Department of Chemistry
- University of Zurich
- CH-8057 Zurich
- Switzerland
| |
Collapse
|
22
|
Felber M, Alberto R. (99m)Tc radiolabelling of Fe3O4-Au core-shell and Au-Fe3O4 dumbbell-like nanoparticles. NANOSCALE 2015; 7:6653-60. [PMID: 25797603 DOI: 10.1039/c5nr00269a] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
The development of nanoparticle-based dual-modality probes for magnetic resonance imaging (MRI) and positron emission tomography (PET) or single photon emission computed tomography (SPECT) is increasingly growing in importance. One of the most commonly used radionuclides for clinical SPECT imaging is (99m)Tc and the labelling of Fe3O4 nanoparticles with (99m)Tc was shown to be a successful strategy to obtain dual-modality imaging agents. In this work, we focus on gold containing magnetic nanomaterials. The radiolabelling of magnetic Fe3O4-Au core-shell and Fe3O4-Au dumbbell-like nanoparticles with the [(99m)Tc(CO)3](+) fragment is described. The key elements for this (99m)Tc labelling approach are novel coating ligands, consisting of an anchor for the Au surface, a polyethylene glycol linker and a strong chelator for the [(99m)Tc(CO)3](+) moiety.
Collapse
Affiliation(s)
- M Felber
- Department of Chemistry, University of Zurich, Winterthurerstrasse 190, CH-8057 Zurich, Switzerland.
| | | |
Collapse
|